Aegis Micronized Formulation Patent Extends Intravail® Scope of Use to Poorly Soluble Drugs

SAN DIEGO, CA May 27, 2014 — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,530,463 extending the use of its Intravail®  transmucosal absorption enhancement technology to poorly soluble drugs.

Formulation of micronized drug nanoparticles in combination with Aegis’ Intravail® alkyl saccharide transmucosal absorption enhancers permits substantially higher doses of poorly absorbed drugs to be absorbed into systemic circulation via intranasal administration.  Because the volume of drug formulation that may be administered intranasally is limited to approximately 150 µL per precisely metered spray, it is necessary to prepare relatively high concentrations of drug in these small volumes in order to meet a drug’s therapeutic dose requirement in an individual spray. Poor solubility for certain drugs makes this difficult or impossible. Dramatically enhanced absorption of poorly soluble drugs can now be achieved by combination of micronized drug nanoparticles with Intravail® extending the scope of applications of the Intravail® drug delivery technology.

Human clinical applications to date include Intravail® -based formulations of diazepam, teriparatide, sumatriptan, calcitonin, octreotide, PYY, and exenatide, and more than a dozen additional preclinical applications for peptide, protein, and small molecule drugs.

Aegis continues to expand its patent portfolio, with 19 allowed patents and more than 60 additional patent applications currently pending worldwide.

To receive future press releases directly via email click here and enter your email address in the sign-up box at the bottom of the page.


About Aegis Therapeutics

Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses.  Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit: